v3.26.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Current assets    
Cash $ 2,077,842 $ 619,520
Accounts receivable, net of allowances of $69,641 and $61,773 as of December 31, 2025 and 2024, respectively 217,263 113,108
Inventory 225,253 219,764
Prepaid expenses and other current assets 241,145 180,853
Current assets held for disposition 123,313
Total current assets 2,761,503 1,256,558
Property and equipment, net 386,165 466,684
Lease right of use 1,286,217 1,493,620
Intangible assets, net 1,325,145 3,275,931
Goodwill 5,878,986 5,878,986
Investment in NAYA Therapeutics 2,466,810
Noncurrent assets held for disposition 32,484,707
Total assets 20,220,124 46,077,014
Current liabilities    
Accounts payable and accrued liabilities 2,034,057 3,113,660
Accrued compensation 285,946 713,483
Deferred revenue 721,897 602,359
Lease liability, current portion 208,987 181,132
Additional payments for acquisition, current portion 3,925,000 2,500,000
Derivative liability 1,881,078
Other current liabilities 410,000
Current liabilities held for disposition 4,294,521
Total current liabilities 10,331,629 17,868,448
Lease liability, net of current portion 1,171,075 1,395,612
Liability for excess losses of equity method investee 448,474 479,768
Notes payable – net of current portion 744,725 1,128,713
Deferred tax liability 163,115
Additional payments for acquisition, net of current portion 300,000 5,000,000
Total liabilities 12,995,903 26,035,656
Mezzanine equity    
Series C-2 Preferred Stock (mezzanine) $1,000.00 par value; 20,000 shares authorized; 3,004 and 8,576 issued and outstanding as of December 31, 2025 and 2024, respectively. 7,457,000
Stockholders’ equity    
Common Stock, $.0001 par value; 6,250,000 shares authorized; 477,366 and 3,111 issued and outstanding as of December 31, 2025 and 2024, respectively 239 37
Additional paid-in capital 96,187,026 49,537,054
Accumulated deficit (91,369,403) (67,327,733)
Total stockholders’ equity 7,224,221 12,584,358
Total liabilities, mezzanine, and stockholders’ equity 20,220,124 46,077,014
Series C-1 Preferred Stock [Member]    
Stockholders’ equity    
Preferred stock value 30,375,000
Series C-2 Preferred Stock [Member]    
Stockholders’ equity    
Preferred stock value 2,406,359
Nonrelated Party [Member]    
Current assets    
Note receivable 5,029,770
Current liabilities    
Notes payable , net 1,054,664 5,173,293
Related Party [Member]    
Current assets    
Note receivable 1,085,528 1,220,528
Current liabilities    
Notes payable , net $ 220,000 $ 880,000